rabies vaccine
Vaccineexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
4
Phase 4
0
Earliest trial started Aug 1, 2012 (NCT02491541)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Lyssavirus rabiesImmunity, active
Lyssavirus rabies immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- changchun werersai
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07028801 | Phase 3 | Jul 31, 2025 | AIM Therapeutics Inc. |
| NCT04852068 | Phase 3 | Apr 10, 2021 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
| NCT06078423 | Phase 3 | Oct 19, 2019 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Government of China, Sponsor GmbH |
| NCT02491541 | Phase 3 | Aug 1, 2012 | Government of China |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | For profit | 2 | 2 | 1 | 2019 |
| Government of China | Government | 2 | 1 | 1 | 2012 |
| AIM Therapeutics Inc. | For profit | 1 | 1 | 1 | 2025 |
| Sponsor GmbH | Academic/Hospital | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1